This site is intended for health professionals only!

Published on 14 June 2010

Share this story:

Senexis sign agreement with O2h

teaser

Executives from Senexis Limited has signed an agreement with O2h  under which O2h will provide Senexis with chemistry services to support a patent filing on a novel chemical series that have shown potential in pre-clinical models, as disease modifying treatments for Alzheimer’s Disease.

Dr. Mark Treherne, CEO of Senexis said that he appreciated O2h’s continual support over the last 4 years in being a reliable chemistry partner, providing flexible multi-FTE chemistry support to the company.

Dr David Scopes, CSO at Senexis said “We have had a long collaboration with O2h and are happy that it is supporting us to further our programs into the important stage of patent applications. Senexis is again leveraging O2h’s expertise on the synthetic chemistry methodology underpinning our lead compounds.”

Sunil Shah, CEO, O2h “We have an incredibly good relationship and I was very happy learn about the positive Senexis data from their pre-clinical studies which allowed the Wellcome Trust to continue supporting this programme.”

02h



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine